Analyzing Surmodics (NASDAQ:SRDX) & Autonomix Medical (NASDAQ:AMIX)

Autonomix Medical (NASDAQ:AMIX) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Profitability

This table compares Autonomix Medical and Surmodics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-542.11%	-236.92%
Surmodics	-9.15%	-3.79%	-2.55%

Valuation & Earnings

This table compares Autonomix Medical and Surmodics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$15.43 million	($16.07)	-0.25
Surmodics	$126.08 million	4.55	-$11.54 million	($0.81)	-49.38

Surmodics has higher revenue and earnings than Autonomix Medical. Surmodics is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Autonomix Medical and Surmodics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	0	0	1	0	3.00
Surmodics	0	4	0	0	2.00

Autonomix Medical currently has a consensus price target of $28.00, indicating a potential upside of 608.86%. Surmodics has a consensus price target of $50.00, indicating a potential upside of 25.00%. Given Autonomix Medical’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Autonomix Medical is more favorable than Surmodics.

Insider & Institutional Ownership

10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 96.6% of Surmodics shares are held by institutional investors. 32.4% of Autonomix Medical shares are held by company insiders. Comparatively, 8.9% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About Surmodics

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.